{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Gastrointestinal+Malignancies&page=18",
    "query": {
      "condition": "Advanced Gastrointestinal Malignancies",
      "page": 18
    },
    "page_size": 10
  },
  "pagination": {
    "page": 18,
    "page_size": 10,
    "total_count": 2243,
    "total_pages": 225,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Gastrointestinal+Malignancies&page=19&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Gastrointestinal+Malignancies&page=17&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T10:58:07.294Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01929941",
      "title": "An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor",
        "Hodgkin's Lymphoma",
        "NHL (Non-Hodgkin Lymphoma)",
        "Pancreatic Cancer",
        "Breast Cancer",
        "UC (Ureter and Urethera)",
        "Advanced Cancer",
        "Metastatic Cancer"
      ],
      "interventions": [
        {
          "name": "INCB047986",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "nab-paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2013-09",
      "completion_date": "2014-08",
      "has_results": false,
      "last_update_posted_date": "2018-01-17",
      "last_synced_at": "2026-11-19T10:58:07.294Z",
      "location_count": 3,
      "location_summary": "Atlanta, Georgia • Nashville, Tennessee • Dallas, Texas",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01929941"
    },
    {
      "nct_id": "NCT00057395",
      "title": "A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Solid Malignancies",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Esophageal Neoplasms",
        "Hepatocellular Carcinoma",
        "Colorectal Neoplasms",
        "Ovarian Neoplasms",
        "Pancreatic Neoplasms",
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "Aroplatin (Liposomal NDDP, L-NDDP)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aronex Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-11-19T10:58:07.294Z",
      "location_count": 1,
      "location_summary": "Santa Monica, California",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00057395"
    },
    {
      "nct_id": "NCT00026364",
      "title": "ZD 1839 Plus Combination Chemotherapy in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Colorectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "gefitinib",
          "type": "DRUG"
        },
        {
          "name": "irinotecan hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "leucovorin calcium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2001-11",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-03-21",
      "last_synced_at": "2026-11-19T10:58:07.294Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00026364"
    },
    {
      "nct_id": "NCT03948763",
      "title": "A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms",
        "Carcinoma, Non-Small-Cell Lung",
        "Pancreatic Neoplasms",
        "Colorectal Neoplasms"
      ],
      "interventions": [
        {
          "name": "V941",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2019-06-26",
      "completion_date": "2022-08-25",
      "has_results": true,
      "last_update_posted_date": "2025-01-28",
      "last_synced_at": "2026-11-19T10:58:07.294Z",
      "location_count": 10,
      "location_summary": "Gilbert, Arizona • Duarte, California • San Francisco, California + 7 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03948763"
    },
    {
      "nct_id": "NCT00096707",
      "title": "Dose Escalation Trial of 2-Deoxy-D-Glucose (2DG) in Subjects With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lung Cancer",
        "Breast Cancer",
        "Pancreatic Cancer",
        "Head and Neck Cancer",
        "Gastric Cancer"
      ],
      "interventions": [
        {
          "name": "2-deoxy-D-glucose (2DG)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Threshold Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2004-02",
      "completion_date": "2008-07",
      "has_results": false,
      "last_update_posted_date": "2009-04-29",
      "last_synced_at": "2026-11-19T10:58:07.294Z",
      "location_count": 3,
      "location_summary": "Miami, Florida • Indianapolis, Indiana • San Antonio, Texas",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00096707"
    },
    {
      "nct_id": "NCT03095781",
      "title": "Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Colorectal Adenocarcinoma",
        "Metastatic Pancreatic Adenocarcinoma",
        "Recurrent Colorectal Carcinoma",
        "Recurrent Pancreatic Carcinoma",
        "Stage III Colorectal Cancer",
        "Stage III Pancreatic Cancer",
        "Stage IIIA Colorectal Cancer",
        "Stage IIIB Colorectal Cancer",
        "Stage IV Colorectal Cancer",
        "Stage IV Pancreatic Cancer",
        "Stage IVA Colorectal Cancer",
        "Stage IVA Pancreatic Cancer",
        "Stage IVB Colorectal Cancer",
        "Stage IVB Pancreatic Cancer",
        "Unresectable Pancreatic Carcinoma"
      ],
      "interventions": [
        {
          "name": "XL888",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 47,
      "start_date": "2017-07-07",
      "completion_date": "2021-06-10",
      "has_results": true,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-11-19T10:58:07.294Z",
      "location_count": 3,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03095781"
    },
    {
      "nct_id": "NCT04957511",
      "title": "Gut Microbiome and Treatment for Gynecological Cancer Patients Receiving Immunotherapy",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Gynecologic Cancer",
        "Immunotherapy",
        "Gut Microbiome"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Viome",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 30,
      "start_date": "2021-06-29",
      "completion_date": "2026-06",
      "has_results": false,
      "last_update_posted_date": "2025-01-29",
      "last_synced_at": "2026-11-19T10:58:07.294Z",
      "location_count": 1,
      "location_summary": "Orlando, Florida",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04957511"
    },
    {
      "nct_id": "NCT05091528",
      "title": "A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HER2-positive Breast Cancer",
        "HER2-positive Gastric Cancer",
        "HER2-positive Colorectal Cancer",
        "HER2-expressing Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "SBT6050",
          "type": "DRUG"
        },
        {
          "name": "trastuzumab deruxtecan",
          "type": "DRUG"
        },
        {
          "name": "tucatinib",
          "type": "DRUG"
        },
        {
          "name": "trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "capecitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Silverback Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2022-02-08",
      "completion_date": "2022-07-07",
      "has_results": true,
      "last_update_posted_date": "2022-08-18",
      "last_synced_at": "2026-11-19T10:58:07.294Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05091528"
    },
    {
      "nct_id": "NCT05229900",
      "title": "A Study of SGN-ALPV in Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ovarian Neoplasms",
        "Endometrial Neoplasms",
        "Carcinoma, Non-Small-Cell Lung",
        "Stomach Neoplasms",
        "Gastroesophageal Junction Carcinoma",
        "Uterine Cervical Neoplasms",
        "Testicular Neoplasms"
      ],
      "interventions": [
        {
          "name": "SGN-ALPV",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seagen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2022-04-21",
      "completion_date": "2023-12-13",
      "has_results": false,
      "last_update_posted_date": "2025-02-10",
      "last_synced_at": "2026-11-19T10:58:07.294Z",
      "location_count": 7,
      "location_summary": "Fresno, California • New Haven, Connecticut • Wellington, Florida + 4 more",
      "locations": [
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Wellington",
          "state": "Florida"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05229900"
    },
    {
      "nct_id": "NCT02554812",
      "title": "A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Cancer"
      ],
      "interventions": [
        {
          "name": "Avelumab",
          "type": "DRUG"
        },
        {
          "name": "Utomilumab",
          "type": "DRUG"
        },
        {
          "name": "PF-04518600",
          "type": "DRUG"
        },
        {
          "name": "PD 0360324",
          "type": "DRUG"
        },
        {
          "name": "CMP-001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 409,
      "start_date": "2015-11-09",
      "completion_date": "2023-03-23",
      "has_results": true,
      "last_update_posted_date": "2024-07-30",
      "last_synced_at": "2026-11-19T10:58:07.294Z",
      "location_count": 57,
      "location_summary": "Encinitas, California • La Jolla, California • Los Angeles, California + 23 more",
      "locations": [
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02554812"
    }
  ]
}